Highlights

  • National rollout of Promarker D and Promarker Eso to begin on 26 October 2026.
  • Tests distributed through exclusive pathology partner Healius.
  • Initial private-pay prices of $495 for Promarker D and $997 for Promarker Eso.
  • Promarker Endo commercial release targeted for January to March 2027.

Diagnostics developer Proteomics International Laboratories Ltd (ASX:PIQ) prepared to take two Promarker blood tests beyond their controlled Australian release and into national distribution. Working with pathology partner Healius, the company scheduled a broader rollout while continuing preparations for a separate endometriosis test.

Getting Collection Centres Ready

Field sales teams have finished training on both tests, such as their intended clinical uses and how clinicians and patients can access them. Proteomics International and Healius have also agreed joint sales and marketing plans to build clinician awareness, provide education and support appropriate referrals.

Systems and operational processes are expected to go live on 26 October, after which Healius collection centres will accept patients for blood collection and process payments. The tests will initially be available on a private-pay basis at $495 for Promarker D and $997 for Promarker Eso.

How the Partners Divide the Work

Proteomics International will continue to perform laboratory testing at its NATA-accredited facility and provide clinical reporting, scientific and medical support, and quality and regulatory compliance. Healius will support specimen collection, pathology distribution and clinician engagement through its national network.

Chief executive David Morris described the national rollout as a significant milestone in bringing the Promarker portfolio to Australian clinicians and patients. Healius Group Executive Anthea Muir said the partnership combines Healius’ collection network and clinician relationships with Proteomics International’s specialist testing capability.

The Next Promarker Product

On 13 October 2026, Proteomics International announced it had finished refinement and independent validation of the model behind its Promarker Endo blood test for endometriosis. Its stated expectation is to make Promarker Endo commercially available in the January to March 2027 quarter, conditional on clinical deployment and quality, accreditation and regulatory requirements.

The business indicated the systems, collection processes and clinician engagement established for the current rollout should support the introduction of Promarker Endo. It noted that, as the Promarker portfolio is at an early stage of commercialisation, revenue under the distribution agreement cannot yet be reliably estimated.

Early Commercialisation Priorities